Overview

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-09-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).

Phase:

PHASE3

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

elexacaftor, ivacaftor, tezacaftor drug combination
ivacaftor